FA
GDRX icon

Friess Associates’s GoodRx Holdings GDRX Stock Holding History

Friess Associates’s Portfolio GDRX Stock Details GDRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-51,000
Closed -$2.84M – 111
2020
Q3 		$2.84M Buy
+51,000
New +$2.7M 0.25% 68

Other funds holding GDRX

FPM
Francisco Partners Management San Francisco, California $292M AUM 34.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SLG
Silver Lake Group Menlo Park, California $3.68B AUM 7.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Tiger Global Management
Tiger Global Management New York $22.8B AUM 30.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
LSCM
Light Street Capital Management Palo Alto, California $534M AUM 59.08% 1-Year Est. Return
ZCI
Zevenbergen Capital Investments Edmonds, Washington $4.38B AUM 56.68% 1-Year Est. Return

Friess Associates's GDRX Position: Q4 2020 in Review

Friess Associates sold out of GoodRx Holdings (GDRX) in Q4 2020, closing a stake of 51,000 shares — an estimated $2.84M sold.

Friess Associates first reported a position in GDRX in Q3 2020 and held it in 1 quarter. The position peaked at $2.84M in Q3 2020. 192 funds tracked by Wall St. Rank hold GDRX as of Q4 2020.

  • Friess Associates reported no remaining GoodRx Holdings position as of Q4 2020 after selling out during the quarter.
  • Friess Associates sold 51,000 GoodRx Holdings shares in Q4 2020, an estimated $2.84M.
  • Friess Associates first reported a position in GoodRx Holdings in Q3 2020 and held it in 1 quarter.
  • Friess Associates's GoodRx Holdings position peaked at $2.84M in Q3 2020.
  • 192 funds tracked by Wall St. Rank held GoodRx Holdings as of Q4 2020.

Based on Friess Associates's 13F filing for Q4 2020, filed 12 Feb 2021.